GEN-MKT-18-7897-A
Oct 10, 2016 | Biopharma, Blogs | 0 comments
By the End of 2024, the peptide therapeutics market value is expected to reach US$46.6 billion1. However, peptide therapeutics present some of the toughest analytical challenges for bioanalytical quantification. Large molecule therapeutics often may not fragment well for MS/MS analysis and often the case upon digestion in a complex biologic matrix this leads to an even higher background and potential for interferences.
To keep up with the pace of developmental therapies, Novartis Pharmaceuticals, along with SCIEX application specialists, recently developed a validated method to quantify pasireotide, a therapeutic peptide used to treat Cushing’s disease, in human plasma samples. The complete article was published in Analytical Chemistry and highlights how SelexION Technology on a QTRAP system can be used to increase selectivity for the accurate and sensitive quantitation of the difficult peptide therapeutic. To summarize the article, pasireotide, a therapeutic cyclic peptide exhibits poor fragmentation efficiency for multiple reaction monitoring (MRM) detections. Therefore, to increase the overall sensitivity of the assay, a DMS multiple ion monitoring (MIM) approach was explored. This method, utilizing the SelexION DMS cell on a QTRAP 6500, overcomes the sensitivity challenge in the typical MRM method due to the poor fragmentation of the analyte. What is great about this is the Pasireotide Method was developed and validated for bioanalytical analysis in human plasma down to 0.01 ng/mL, approximately 5-fold better than an MRM based method without using DMS separation – talk about improvements!
Over the past few years, researchers have needed to overcome the challenges associated with peptide bioanalysis in order to keep up with market demands. One way to do this according to Evgueni Fedorov, Executive Director, R&D, BIOTRIAL Bioanalytical ServicesOne, is to increase separation power. This was demonstrated in his webinar with SCIEX, where he showed how SelexION DMS technology on a QTRAP system can be used to enhance the selectivity of another challenging large therapeutic peptide, exenatide.
The Take-Away
References
For more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.
PFAS are increasingly at the center of regulatory change, scientific research, and industry discussion worldwide. As analytical capabilities improve and expectations around environmental responsibility continue to evolve, understanding the role PFAS play, and how they are being addressed, has never been more important. This blog provides an overview of what PFAS are, why they matter, and how responses from regulators and industry are changing.
Pesticides are widely used in agriculture to protect crops and maintain yield, but their presence in food must be carefully monitored. To safeguard consumers, regulatory authorities worldwide set maximum residue limits (MRLs), often at very low concentrations and across a wide range of compound classes.
Posted by
You must be logged in to post a comment.
Share this post with your network